Reaction

Acute Graft Versus Host Disease In Liver reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 712 reports · 42 co-occurring drugs

As of the last recalculation, Acute Graft Versus Host Disease In Liver appears in 712 FAERS reports alongside 42 co-occurring drug terms. The strongest observed disproportionality signal is BUSULFAN (PRR 259.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Busulfan	117	259.9	261.9
Fludarabine Phosphate	230	252.1	253.6
Thiotepa	73	248.9	250.8
Anti-Thymocyte Globulin (Rabbit)	49	190.6	191.8
Cyclosporine	265	110.3	110.6
Melphalan Hydrochloride	79	103.5	103.8
Micafungin Sodium	27	96.7	97.0
Melphalan	68	96.5	96.8
Mycophenolate Mofetil	273	94.7	94.9
Mycophenolate Mofetil Hydrochloride	273	94.5	94.7
Ganciclovir	26	77.0	77.2
Sirolimus	33	75.0	75.2
Ganciclovir Sodium	26	74.5	74.7
Alemtuzumab	45	72.5	72.7
Tacrolimus Ointment 0.1%	190	60.5	60.6
Tacrolimus Extended-Release Capsules	190	60.3	60.4
Tacrolimus	219	58.6	58.7
Posaconazole Delayed-Release	19	51.9	52.0
Voriconazole	44	45.1	45.1
Methylprednisolone	161	43.7	43.8
Posaconazole	23	42.7	42.8
Voriconazole Injection	29	40.7	40.7
Cyclophosphamide Injection, Solution	180	39.4	39.5
Cyclophosphamide	180	39.4	39.5
Cyclophosphamide For Injection	180	39.4	39.5
Itraconazole	15	38.3	38.4
Basiliximab	15	38.1	38.1
Mesna Injection	10	35.9	35.9
Mesna	10	35.2	35.2
Cytarabine	61	32.4	32.4
Filgrastim	38	31.1	31.2
Hydrocortisone Sodium Succinate	8	25.1	25.2
Mycophenilic Acid	17	24.5	24.6
Azacitidine For	14	22.9	22.9
Blinatumomab	8	22.7	22.7
Ruxolitinib	50	21.9	21.9
Azacitidine	21	21.3	21.3
Ursodiol	15	20.5	20.6
Ursosiol	12	18.3	18.3
Etoposide	40	16.8	16.8
Ifosfamide	11	15.2	15.2
Imatinib	9	15.1	15.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.